ponesimod
Selected indexed studies
- Ponesimod. (, 2012) [PMID:34383396]
- Ponesimod to treat multiple sclerosis. (Drugs Today (Barc), 2021) [PMID:34909803]
- Ponesimod: First Approval. (Drugs, 2021) [PMID:33939119]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ponesimod. (2012) pubmed
- Ponesimod to treat multiple sclerosis. (2021) pubmed
- Ponesimod: First Approval. (2021) pubmed
- Ponesimod. (2006) pubmed
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (2021) pubmed
- Ponesimod for the treatment of relapsing multiple sclerosis. (2020) pubmed
- Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis. (2023) pubmed
- Ponesimod. (2021) pubmed
- Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data. (2022) pubmed
- Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. (2023) pubmed